{
    "nctId": "NCT05427617",
    "briefTitle": "Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer",
    "officialTitle": "Clinical Application of Circulating Tumor DNA (ctDNA) to Guided the Late-Line Treatment for Patients With Late-Stage Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer, Circulating Tumor DNA, Gene Abnormality",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 223,
    "primaryOutcomeMeasure": "Disease Control Rate (DCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Recent progression of TNBC after multiple lines of chemotherapy or of HR+ or HER2+ MBC after multiple lines of endocrine or targeted therapy;\n* No available recommendation for the next treatment regimen;\n* An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;\n* An updated, available pathological HR/HER2 status for metastasis;\n* According to RECIST 1.1 standard, there should be at least one measurable target lesion;\n* The expected survival time is \\> 3 months;\n* Those aged 18-70 years old;\n* Liver and kidney function and blood routine test meet the following conditions: Neutrophil \\> 2.0g/l, Hb \\> 9g / L, PLT \\> 100g / L; ALT and AST \\< 2.5ULN; TBIL \\< 1.5ULN; Cr \\< 1.0ULN\n* Signing informed consent;\n* Those willing to accept polygenic testing.\n\nExclusion Criteria:\n\n* Patients with multiple primary tumors;\n* Those who are unable to obtain blood samples;\n* Those with a history of immunodeficiency or organ transplantation;\n* Those with abnormal cardiac function or previous history of myocardial infarction or serious arrhythmia;\n* The researchers think it is not suitable to participate in this experiment.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}